Draft US bill on payments to physicians imposes strict disclosure rules
This article was originally published in RAJ Devices
Senators Charles Grassley (Republican - Iowa) and Herb Kohl (Democrat - Wisconsin) have reintroduced legislation that seeks to impose strict rules for disclosing financial relationships between medical device companies and doctors, including requiring the creation of a national registry of industry payments to physicians1. The Physician Payments Sunshine Act now has a lower payment disclosure threshold - namely requiring drug and device companies to publicly report the payments, consulting fees, honoraria and other “transfers” they give to doctors over $100 every year. In the previous version of the bill (S 2029), the threshold was $5002. The information would be posted on a federal website for public viewing in 2011.
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.